Harmony Biosciences (HRMY) Announce Sandip Kapadia as CFO
- Futures slip as focus shifts to earnings from tech-related firms
- Analysts Positive, Raise PTs as IBM (IBM) Tops Market Estimates and Reaffirms Guidance
- Tesla's (TSLA) Musk says data logs from crashed vehicle show Autopilot was not enabled, car did not purchase FSD
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the appointment of Sandip Kapadia as Chief Financial Officer effective March 29, 2021. Mr. Kapadia is an accomplished executive with more than two decades of operational experience in leading finance operations, supporting commercialization, raising capital and providing strategic guidance within the healthcare sector.
"We are very pleased to welcome Sandip to Harmony. His broad and deep financial leadership experience will be an asset as we continue to build upon the momentum of 2020. Sandip's expertise as a strategic and tactical financial executive will contribute significantly to our business as we plan to deliver long-term growth to our company and key stakeholders," said John C. Jacobs, Harmony's President and Chief Executive Officer.
Mr. Kapadia has over 25 years of industry experience across multiple therapeutic areas and has provided strategic financial oversight and guidance to companies both in the United States and abroad. Most recently, he served as the Chief Financial Officer at Intercept, where he built upon the company's key functional capabilities, developed and executed financial and capital strategies to prepare for commercial launch and raised over $700 million in various financings. Prior to Intercept, Mr. Kapadia spent the majority of his career at Novartis and Novartis affiliates in the United States, Switzerland, the Netherlands and the United Kingdom, where he held positions of varying levels of responsibility, including most recently serving as Chief Financial Officer of North America at Novartis's generic division, Sandoz. He currently serves on the board of directors of Passage Bio, Inc., Molecular Partners AG and VectivBio Holding AG.
Mr. Kapadia is a Certified Public Accountant and holds a MBA from Rutgers University and a BBA from Montclair State University.
"I am delighted to join the team at Harmony and contribute to the company's continued success. I look forward to helping the company create long term value for investors, healthcare providers and patients, true to its mission," said Mr. Kapadia.
Mr. Kapadia replaces Susan Drexler who will be stepping down as Chief Financial Officer as of March 29, 2021 to pursue other career opportunities.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Parsons Corporation (PSN) has elected Carey Smith as chief executive officer
- Blink Charging (BLNK) Announces Distribution Agreement with EV Transportation Services, Inc. for the Blink IQ 200-M Portable EV Charger
- 180 Life Sciences Corp (ATNF) Confirms Collection of All Patient Data for Phase 2b Dupuytren’s Disease Trial